Over 170 kinds of diabetes drugs are under research to deal with the challenge of diabetes

11/11/2016

RDPAC released the report ofFaces of Innovation: Meeting the Challenge of  Diabetes


 

[November 11, 2016, Beijing] With the coming of the 25th“World  Diabetes Day”, R&D Based Pharmaceutical Association Committee of China  Association of Enterprises with Foreign Investment (RDPAC) releasedFaces of  Innovation: Meeting the Challenge of Diabetestoday in  Beijing. The report reveals the severe disease situation and heavy disease  burden of diabetes in China at present, and the multiple positive significance  of improving the patient's life quality and reducing social disease burden by  enhancing drug innovation and improving drug accessibility.


 High morbidity, low control rate, new innovative diagnosis and treatment are  urgent needed for the heavy disease burden  


 The theme of 2016 World Diabetes Day is “Eyes on Diabetes”, appealing  enhancement for the early diagnosis and treatment of diabetes to prevent the  complications such as sight degeneration, renal failure, and cardiovascular  disease and so on and heavy impact on the patients and their family as well as  society caused by diagnosis.


   

Diabetes  is the number one serious chronic disease in China. According to the statistics  of International Diabetes Federation, China has the largest population who  suffer from diabetes in 2015, reaching 110 million, which means that there are  one-tenth of the Chinese people are suffering from diabetes and its related  disease. The death population caused by diabetes each year is over 1 million,  at the same time, diabetes also causes a variety of complications such as cardiovascular  disease, renal failure, sight degeneration and so on. The medical expenditure  of China used for the treatment of diabetes and its related diseases reaches 50  billion US dollars every year, occupying 13% of the total national health  expenditure, and 80% is used for the treatment of complications. According to  the prediction of International Diabetes Federation, the total health  expenditure ofChinafor diabetes related diseases will reach to 72 billion US dollars by the year  of 2040.  


 

With  the rapid progress of aging society, it can be predicted that China will face  enormous pressure on how to deal with the chronic diseases such as diabetes and  so on in the future. Enhancement of disease control and adopting of innovative treatment  are urgently needed to improve the treatment effect and life quality of  patient, and reduce the disease burden of family and the whole society.


 At present, there is still a large gap between China and many other countries  in the field of diabetes treatment and control. The current treatment rate of  diabetes in our country is only 35.6%. Among the patients who accept treatment,  the treatment control rate is 36.3%. That is to say less than 12% of diabetes  patients have got effective treatment control. The lower diagnosis and  treatment rate, the heavier burden of total health expenditure will be. This  situation needs to be improved rapidly.


 

Joining hands to  promote the drug innovation, so as to accelerate to achieve the goal of 2025  chronic disease prevention and control  


  

611.jpg  

Dr. Maarten Hendriks, Medical Vice President Boehringer Ingelheim Great China Region  

 

“For many pharmaceutical companies, diabetes is a focus area, and some 170 drugs* are under research. The need for more effective and convenient drugs with less side-effects is the general direction. Cure of the diabetes is currently not possible, but very recently medicine has been shown to reduce mortality and serious disease complications, which is a unique and major advance in diabetes care.” Dr. Maarten Hendriks, Medical Vice President Boehringer Ingelheim Great China Region also says that ultimately many patient want personalized treatment, so that despite the straight jacket the disease causes they can have a normal life.

 

621.jpg  

Dr. Luo Tianhong, Head of Medical Affairs of Sanofi China,  


 

Type  2 diabetes is a kind of progressive disease, many drugs have effect  on the control of blood sugar of patient initially, but as time goes on, they  may lose effect. Therefore, new drugs or replacement therapy are needed to  control the blood sugar. When this circumstance occurs, the access that patient  gets other drugs is of great importance. If diabetes is well controlled, the  complications will be less and the total health expenditure will be also less. Dr.  Luo Tianhong, Head of Medical Affairs of Sanofi China, expressed that: “It  needs the joint effort from the government, association, academy, enterprise  and healthcare professionals of diabetes at all levels. And it is necessary to  strengthen the standardized application of therapeutic schemes, establish  innovative systematic monitoring system, so as to improve the compliance of  patients, and improve the disease management level and life quality of  patients.”“Except high quality innovative drugs, the whole process health management of diabetes patient is particularly important for the disease control.” Dr. Luo Tianhong, Head of Medical Affairs of Sanofi China, expressed that: “It needs the joint effort from the government, association, academy, enterprise and healthcare professionals of diabetes at all levels. and it is necessary to strengthen the standardized application of therapeutic schemes, establish innovative systematic monitoring system, so as to improve the compliance of patients, and improve the disease management level and life quality of patients.”  


 

631.jpg  

Mike Dethick, Managing Director of RDPAC  

   

A  study in the United States shows that the drug compliance of patient will  decrease by 25% when the self-paid ratio increases twice. InChina, the  problem of drug compliance decrease caused by self-paid ratio increase will  cause the same results in prediction. So, facing the challenge of chronic  diseases such as diabetes and so on, all sectors of society should join hands  and take actions. It is necessary to continuously develop better innovative  drugs, and guarantee the accessibility and compliance of these treatment  methods for patients. Mike Dethick, Managing Director of RDPAC, says: we are  very glad to see that “Healthy China2030”Planning Outlineclearly puts  forward the solution for the problem of “fairness and accessibility”,  strengthening the effective intervention on main health problem in different  life stages and main effective factors, and benefiting the entire population  and covering the whole life circle, to achieve national health in a higher  level. The government has been taking measures, as the participant of  pharmaceutical industry, we should pay more attention to the innovation to meet  the requirements of diabetes prevention and control. 


 

* Based on PhRMA's report  

Related articles: